RxDoctor Payments Data

Karan Kochhar, MD

Internal Medicine · Clark, NJNPI 1285167536

Payments from drug & device makers

$3,203in general payments, 2019–2025

Across 162 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$659
  • Novo Nordisk$566
  • Exact Sciences$467
  • Amgen$309
  • Lilly USA, LLC$233
  • Pfizer$217
  • plus $752 from 11 others

What the payments were for

  • Food & beverage$3,203100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,203 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$63,271
Medicare patients
196
Services billed
1,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$75,707
RybelsusSemaglutide34$72,419
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$41,520
MounjaroTirzepatide12$28,545
JardianceEmpagliflozin27$28,282
FarxigaDapagliflozin Propanediol17$20,113
JanumetSitagliptin Phos/Metformin Hcl12$13,154
JanuviaSitagliptin Phosphate11$10,007
Atorvastatin Calcium264$3,460
Metoprolol Succinate142$2,366
Rosuvastatin Calcium111$1,800
Valsartan32$1,386
Amlodipine Besylate179$1,372
Albuterol Sulfate HfaAlbuterol Sulfate37$1,319
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$566$148,12692 claims
Lilly USA, LLCMounjaro$233$28,54512 claims
AstraZenecaFarxiga$74$20,11317 claims
AbbVieSynthroid$87$1,05116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Clark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →